Want to see SY full AI Analyst Report?
Top Page
So-Young International
(NASDAQ:SY)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.50
▲(26.90% Upside)
Action:Reiterated
Date:07/25/26
The score is held down primarily by weak financial performance—ongoing losses and recent cash burn—despite a comparatively manageable leverage profile. Technicals are mixed with only a short-term bounce versus longer-term weakness, and valuation is not supportive given negative earnings and no dividend data. The earnings call adds upside potential via strong core growth and upbeat guidance, but profitability and cash usage remain key near-term risks.
Positive Factors
Rapid Branded Clinic Growth
The clinic business is becoming a larger engine of growth, supported by network expansion, rising treatment volumes and strong customer adoption. Its increasing revenue contribution can improve platform control and create a more durable position across the medical aesthetics value chain.
Negative Factors
Persistent Consolidated Losses
Despite strong clinic growth, consolidated losses widened, showing that network expansion has not yet translated into company-wide profitability. Continued losses could constrain reinvestment capacity and make the path to sustainable earnings dependent on successful execution and cost control.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid Branded Clinic Growth
The clinic business is becoming a larger engine of growth, supported by network expansion, rising treatment volumes and strong customer adoption. Its increasing revenue contribution can improve platform control and create a more durable position across the medical aesthetics value chain.
Read all positive factors
So-Young International (SY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$243.42M
Dividend YieldN/A
Average Volume (3M)784.25K
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue Growth16.74%
EPS Growth55.76%
CountryUS
Employees2,348
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-1.95
Shares Outstanding84,619,710
10 Day Avg. Volume520,189
30 Day Avg. Volume784,246
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.52
Price to Sales (P/S)1.59
P/FCF Ratio-7.80
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.66
Revenue Forecast (FY)$2.05B
So-Young International Business Overview & Revenue Model
Company Description
So-Young International Inc. manages a digital platform specializing in medical aesthetics and elective healthcare services, serving customers in the People's Republic of China and globally. This online ecosystem enables users to explore content, s...
How the Company Makes Money
So-Young primarily makes money by monetizing its platform’s ability to match consumer demand for medical aesthetic procedures with supply from medical aesthetic service providers. Key revenue streams include: (1) Advertising and marketing services...
So-Young International Earnings Call Summary
Earnings Call Date:May 22, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 31, 2026
Earnings Call Sentiment Positive
The call communicated strong operational and top-line momentum driven by rapid expansion of the branded clinic network, substantial increases in aesthetic center revenue (+~186% YoY), improving clinic-level margins (27% gross margin, +8.4 pp YoY), rising treatment volumes and growing core membership. Management reinforced clinical, supply-chain and training investments and provided confident near-term guidance. Offsetting these positives are widened consolidated net losses, rising cost of revenue and elevated operating expenses tied to expansion, modest declines in non-clinic segments, and a slightly reduced cash balance after funding growth initiatives. On balance the substantive revenue and margin progress at the core clinic business and forward guidance materially outweigh near-term profitability and cash draws tied to scaling.Positive Updates
Strong Top-Line Growth
Total revenue for Q1 2026 was RMB 432.8–433 million, up ~45.6% year-over-year, driven by branded aesthetic center expansion and supply-chain momentum.
Negative Updates
Widening Net Loss
Net loss attributable to So‑Young was RMB 49.2 million in Q1 2026 versus RMB 33.1 million in the prior-year period; non‑GAAP net loss was RMB 46.6 million versus RMB 31.5 million, and basic/diluted loss per ADS widened to RMB 0.48 from RMB 0.02.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Top-Line Growth
Total revenue for Q1 2026 was RMB 432.8–433 million, up ~45.6% year-over-year, driven by branded aesthetic center expansion and supply-chain momentum.
Read all positive updates
Company Guidance
Management guided Q2 aesthetic treatment service revenue of RMB 307–317 million (implying 112.6%–119.5% YoY growth) and reiterated a long‑term 1,000‑center goal, expecting new centers to ramp faster, per‑center revenue to keep climbing and a clear path to profitability as scale and efficiency improve; for context Q1 results and operating metrics included total revenue RMB 432.8M (+45.6% YoY), aesthetic center revenue RMB 282.4M (+185.8% YoY, >65% of total) with a ~27% gross margin (expanded +8.4 ppts YoY, +3.3 ppts QoQ), >148,000 verified treatment visits (+172% YoY), >325,000 verified treatments (+164% YoY), >310,000 active users (63,000+ Level‑3 members), 52% of new customers from referrals, 41 profitable centers and 48 centers with positive operating cash flow (net adds +15 and +9 QoQ), average mature‑center revenue ~RMB7.5M (growth centers ~RMB4.8M; ramp‑up ~RMB2.1M), cash and equivalents ~RMB880M (vs. RMB936.4M at year‑end 2025) and a net loss attributable of RMB49.2M (non‑GAAP loss RMB46.6M).So-Young International Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
64
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.65B | 1.48B | 1.47B | 1.50B | 1.26B | 1.69B |
| Gross Profit | 759.68M | 707.86M | 899.11M | 953.69M | 864.58M | 1.36B |
| EBITDA | -203.21M | -182.19M | -38.39M | 53.96M | -39.99M | 63.39M |
| Net Income | -256.54M | -235.70M | -589.53M | 21.28M | -65.55M | -8.37M |
Balance Sheet | ||||||
| Total Assets | 2.65B | 2.65B | 2.74B | 3.21B | 3.20B | 3.33B |
| Cash, Cash Equivalents and Short-Term Investments | 876.69M | 936.96M | 1.19B | 1.33B | 1.57B | 1.74B |
| Total Debt | 379.00M | 299.90M | 239.88M | 145.77M | 71.26M | 105.89M |
| Total Liabilities | 1.05B | 981.44M | 776.43M | 653.25M | 590.00M | 813.33M |
| Stockholders Equity | 1.49B | 1.55B | 1.84B | 2.44B | 2.50B | 2.45B |
Cash Flow | ||||||
| Free Cash Flow | -302.01M | -302.01M | -88.18M | -28.68M | -128.58M | 39.23M |
| Operating Cash Flow | -105.39M | -105.39M | -25.63M | 22.50M | -112.87M | 84.29M |
| Investing Cash Flow | -42.81M | -42.81M | 257.04M | -202.61M | -572.21M | 339.82M |
| Financing Cash Flow | -63.70M | -63.70M | -21.51M | -100.02M | -13.59M | -216.74M |
So-Young International Technical Analysis
Positive
1.97
Price Trends
1.86
Positive
2.23
Positive
2.64
Negative
Market Momentum
0.13
Negative
67.57
Neutral
68.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SY, the sentiment is Positive. The current price of 1.97 is below the 20-day moving average (MA) of 2.16, above the 50-day MA of 1.86, and below the 200-day MA of 2.64, indicating a neutral trend. The MACD of 0.13 indicates Negative momentum. The RSI at 67.57 is Neutral, neither overbought nor oversold. The STOCH value of 68.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SY.
So-Young International Risk Analysis
So-Young International disclosed 86 risk factors in its most recent earnings report. So-Young International reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Our business is subject to data privacy laws and regulations in jurisdictions other than China. Any failure or perceived failure to comply with such laws and regulations could have a material and adverse impact on our business, financial condition and results of operations. Q4, 2023
So-Young International Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $712.07M | 76.22 | 2.79% | ― | 14.05% | ― | |
68 Neutral | $102.41M | 37.82 | 16.56% | ― | 15.07% | ― | |
66 Neutral | $1.19B | 69.39 | 2.61% | ― | -1.83% | -48.77% | |
55 Neutral | $198.32M | -2.50 | -33.27% | ― | -19.00% | 40.98% | |
52 Neutral | $1.12B | -6.39 | -13.08% | ― | -2.08% | 16.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $243.42M | -8.28 | -15.90% | ― | 16.74% | 55.76% |
* Healthcare Sector Average
SY
So-Young International
2.40
-1.53
-38.93%
CCLD
CareCloud
2.64
-1.07
-28.84%
TDOC
Teladoc
6.33
-1.41
-18.22%
PHR
Phreesia
11.60
-20.39
-63.74%
AMWL
American Well
11.92
4.97
71.51%
GDRX
GoodRx Holdings
3.65
-0.85
-18.89%
So-Young International Corporate Events
So-Young International Names Former Gaotu Executive Nan Shen as CFO
Aug 4, 2026
So-Young International Inc., a Nasdaq-listed Chinese aesthetic treatment platform linking online services with offline procedures and medical devices, continues to build out its vertically integrated model in the country’s fast-growing medic...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.